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Surgical aortic valve replacement (SAVR) is the reference treatment for severe
aortic stenosis (AS). Transcatheter aortic valve implantation (TAVI) has emerged
as an alternative treatment. The aim of the study was to assess if the clinical profile
of octogenarian patients treated surgically before and after the TAVI program ini-
tiation has changed. We retrospectively included consecutive octogenarian
patients, who underwent isolated SAVR, between January 2006 and December
2014 in a single high-volume center. We compared preoperative, peri-operative
and postoperative characteristics before and after the initiation of TAVI (February
2009). 845 patients were included: 229 in the pre-TAVI group (2006-2008;
3 years), 616 in the post-TAVI group (2009-2014; 6 years). Over time, there was
an increased rate of SAVR performed. The mean age was the same, 83.2±2.0
years in the pre-TAVI group, 83.5±2.1 years in the post-TAVI group
(p=0.06). The preoperative characteristics were statistically comparable, except
for history of heart failure (25% in the pre-TAVI group vs 18% in the post-TAVI
group, p=0.04), coronary artery disease (22% in the pre-TAVI group vs 14% in
the post-TAVI group, p=0.01), hypertension (59% in the pre-TAVI group vs 68%
in the post-TAVI group, p=0.02) and obesity (18% in the pre-TAVI group vs 24%
in the post-TAVI group, p=0.03). Peri-operative data and post-operative adverse
events were comparable between both groups. The operative mortality (30-day)
was similar, 5.2% in the pre-TAVI group, 5.5% in the post-TAVI group (p=0.87).
In conclusion, with the emergence of TAVI, the number of octogenarian patients
operated on continued to increase, their preoperative characteristics were clinically
similar and the operative mortality was stable.
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Objective The mechanism involved in the onset of aortic valve (AoV) dis-
ease remains unclear.Our recent work revealed the requirement of the tran-
scription factor Krox20 (EGR2) to regulate fibrillar collagen genes during
AoV formation. Based on 50% decreased expression of KROX20/EGR2 in
diseased human AoV, we examined the phenotype of the Krox20 hetero-
zygous mice with echo and histological analyses.
Methods Krox20-/+ heterozygous mice (n=21) were compared to control
(n=35) at different stages. Quantitative analysis of AoV histology was per-
formed intriplicate for each genotype. We used a high-frequency echocardio-
gram to evaluate the AoV function. 
Results We demonstrated that incomplete invalidation of Krox20 in mutant
mice caused a significant thickening of AoV compared to control group
(145±22μm vs 75±24μm, p=0.01). Within the heterozygous group, we observed
that is thickening involved exclusively the AoV and worsened significantly
during time (>7 month-old vs <7 month-old AoV thickening, 136±48μm vs
102±41μm, p<0001). AoV of Krox20-/+ (E) 18.5 embryo were significantly more
thickened than control embryo leaflet suggesting a beginning of the disease
during the embryonic period. 
Echo analysis showed a significant increased of AoV dysfunction in hetero-
zygous mice vs control (52% vs 27%, p<0.001), Morphometric analysis showed
that the most severe AoV dysfunction were associated with the most thickened
AoV.Histological analysis in mutant mice showed an extra cellular matrix
(ECM) disorganization evocative of myxomatous degeneration including excess
of proteoglycan deposition and reduction of collagen fiber.Concomitant exam-
ination of Human diseased AoV showed a significant decrease in KROX20/
EGR2 expression(p<0.05). COL1A2 was down regulated in diseased Human
AoV (p<0.05) as it was observed in mutant mice.
Conclusion As previously suggested in human, we confirmed that
decreased of Krox20 expression leads to degeneration of aortic leaflet, disor-
ganization of ECM and AoV dysfunction (figure next page).
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Background While admission in the intensive care unit (ICU) has been
regarded as an essential step after transcatheter aortic valve implantation
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(TAVI), the improvement of the results of the technique calls into question
this systematic approach. 
Purpose To evaluate feasibility and safety of TAVI performed without
ICU admission in patients considered at low risk according to simple clinical,
ECG, and echographic criteria. 
Methods Between December 2014 and May 2015, we included in a pro-
spective monocentric cohort study 99 consecutive patients undergoing TAVI.
Low risk group included patients with LVEF >40%, absence of severe pulmo-
nary disease, transfemoral (TF) access, stable hemodynamic state and absence
of complications occurring until 2 hours after the procedure. High risk group
included all other patients. Major in hospital cardiovascular adverse events
were recorded in the two groups (VARC-2 criteria). 
Results The study included 47 men (47.5%) and median age was 84 years
(79-88). Median Euroscore II was 4.1 (3.1-6.6). The balloon expandable
Sapien 3 valve was mainly used (79.6%; n=78), with TF approach and general
anesthesia for the majority of the patients (95.9% and 94.9%). A total 33
patients (33%) considered at low risk were admitted in the conventional car-
diology unit. At follow-up, only one low-risk patient (3.0%) developed a
minor complication (non compressive pericardial effusion with spontaneous
resolution) giving a NPV of the model of 97% (CI:0.84-1.0). Conversely, 21
patients (31.8%) from the high-risk group developed complications (PPV:
31.8%; CI: 0.21-0.44) (Table). 
Conclusion The results of our study suggest that TAVI procedure can be
performed safely without ICU admission in selected patients. This new “min-
imalist” strategy concerned one third of our patients but may probably be
extended considering the relatively low rate of events in the ICU admitted
group. 
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Background the association of severe aortic stenosis and mitral regurgita-
tion (MR) is not rare in patients undergoing transcatheter aortic valve implan-
tation (TAVI). The effect of TAVI on MR and its impact on outcome was
evaluated.
Methods All patients undergoing TAVI in our center were evaluated.
Patients with paravalvular leak or residual stenosis after TAVI were excluded.
Ninety out of 166 patients undergoing TAVI had follow-up data on post-pro-
cedural MR and constituted the patient population. Mitral regurgitation was
graded on a 0-4 scale and divided into two categories for survival analysis,
minimal (none/mild MR [grade 0-1/4]) and significant MR (moderate /severe
MR [grade 2-4/4]). Patients were followed for a median of 427 days for death
and development of heart failure (HF).
Results Average age was 81±6; 49% were male and the average Euroscore
was 22±15. Mitral regurgitation before TAVI was minimal in 52 pts (58%)
and significant in 38 pts (42%). Post TAVI, MR was minimal in 56 pts (62%)
and significant in 34 pts (38%). Sixteen pts (18%)developed worsening MR
with an increase of at least one MR grade post TAVI, 25 pts (28%) has an
improvement in the MR (MR grade was less) and 49 pts (54%) no change
occurred in the MR. Development of significant MR post successful TAVI
was a strong predictor of the development of HF (49±9% vs 70±6%, respec-
tively, p=0.02) as well as the combined end point of death and HF (event free
survival 46%±9% versus 64%±7%).
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Abstract 0352 – Figure: Histological analysis of the aortic valve
Abstract 0205 – Table: Cardiovascular adverse events in the two groups of patients
Post TAVI adverse events Low risk group (n=33) High risk group (n=66)
Death (n=1) 0 1 (1.5%)
New conductive disorder (n=17)
Permanent pacing requirement (n=14)
0
0
17 (17.2%)
14 (14,1%)
Major vascular complications (n=1) 0 1 (1.01%)
Pericardial effusion >10 mm
- cardiac tamponnade (n=2)
- non compressive (n=1)
 0
1 (3%)
 2 (2.02%)
0
TOTAL (n=22) 1 (3%) 21 (31.8%)
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